Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.

Figure 1: Expression of reporter gene constructs derived from the gcy-5, lim-6 and lsy-6 genes. One potential explanation for our observations is that the vector backbone may dictate the packaging of ...

The genetic medicine revolution is underway. Just 18 months ago, very few people in the general population had heard of mRNA vaccines; now, hundreds of millions globally have been vaccinated with one.

Every dog has its day, and Monday was Curia’s as the CDMO got its paws on a new drug manufacturing platform. Curia has enlisted enzymatic DNA production outfit Touchlight to furnish its clients with ...

What Are AAV Vector-Based Therapies? Gene therapies are groundbreaking approaches utilizing viral and non-viral vectors. These vectors introduce therapeutic genes into patient cells to treat diseases, ...

New results have highlighted the advantages of minicircles over plasmids as they avoid unnecessary bacterial backbone sequences due to higher transfection efficiencies and offer benefits especially in ...

Molecular cloning refers to the replication and recombination of DNA molecules. The first cloning experiments were carried out in the 1970s, when restriction endonucleases were discovered. Restriction ...

Touchlight scored another $125 million to boost manufacturing as the company looks to become a leading synthetic DNA producer for genetic medicines. The cell and gene therapy space has exploded in the ...